摘要
目的探讨聚乙二醇干扰素α-2b(Peg IFNα-2b)联合恩替卡韦(ETV)治疗聚乙二醇干扰素α-2b应答不佳HBeAg阳性慢性乙型肝炎的疗效。方法选取2013年4月至2015年4月本院收治的42例Peg IFNα-2b应答不佳HBeAg阳性慢性乙型肝炎患者,随机分为观察组及治疗组,各21例。观察组在Peg IFNα-2b治疗基础上加用ETV治疗,对照组直接换用ETV治疗,治疗时间均为52周。观察两组在12、24、52周时ALT复常率、HBV DNA转阴率、HBeAg转换率及HBsAg水平。结果治疗52周,两组ALT复常率、HBV DNA转阴率、HBeAg转换率比较差异均有统计学意义(P<0.05),HBsAg转阴率比较差异无统计学意义。两组治疗52周,期间均未出现病毒突破和生化突破。结论 Peg IFNα-2b联合ETV治疗生化应答率、病毒学应答率和血清学应答率均高于ETV单药治疗,值得临床推广应用。
Objective To investigate the efficacy of PEG interferon α-2 b(Peg IFN α-2 b) combined with entecavir(ETV) in the treatment of chronic hepatitis B with poor response to peg interferon α-2 b.Methods 42 patients from April 2013 to April 2015 in our hospital with chronic hepatitis B with poor response to Peg IFNα-2 b were randomly divided into observation group and treatment group,with 21 cases in each group.The observation group was treated with ETV on the basis of Peg IFNα-2 b treatment,while the control group was treated with ETV directly for 52 weeks.The ALT normalization rate,HBV DNA negative conversion rate,HBeAg conversion rate and HBsAg level were observed at 12,24 and 52 weeks.Results After 52 weeks of treatment,there was significant difference in ALT normalization rate,HBV DNA negative conversion rate and HBeAg conversion rate between the two groups(P<0.05),there was no significant difference in HBsAg negative conversion rate.No viral or biochemical breakthroughs occurred during 52 weeks of treatment in both groups.Conclusion Peg IFNα-2 b combined with ETV has higher biochemical response rate,virological response rate and serological response rate than ETV alone,which is worthy of clinical application.
作者
戴颖
陈川英
陈芳
孙杨安
Dai Ying;Chen Chuanying;Chen Fang;Sun Yang'an(Department of Hepatopathy 3,Nanchang Ninth Hospital,Nanchang,Jiangxi,330006,China;The First Department of Surgery,Jiangxi Tomor Hospital,Nanchang,Jiangxi,330006,China)
出处
《当代医学》
2020年第10期97-99,共3页
Contemporary Medicine
